

RECEIVED
JUL 27 2001
TECH CENTER 2632/2900

USPTO Form 149
Patent and Trademark Office
U.S. Department of Commerce

Attorney Docket No.
01107.00103

Serial No.
09/784,005

**INFORMATION DISCLOSURE
CITATION**

Applicant(s): **Vogelstein, et. al.**

Sheet 2 of 2

Filing Date: **February 16, 2001**

Group: **1645**

U.S. PATENT DOCUMENTS

Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Country	Class	Subclass	Translation	
						YES	NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

B21	Mancinelli, L., et al., "Pharmacogenomics: The Promise of Personalized Medicine," AAPS Pharmsci 2000; 2 (1) article 4 (http://www.pharmsci.org/scientificjournals/pharmsci/journal/4b.html).
	Mendible JC, "Pharmacogenetics: Medicines Taylored Just for You," January 3, 2000; http://209.52.189.2/articles.cfm,molecular_medicine/31171 .
	Munker, T., "Pharmacogenomics: Personalized Drugs And Personalized Medicine," http://www.globaltechnoscan.com/6march-12march/Pharmacogenomics.html .
	Rastogi, M., "An Overview of Pharmacogenomics," http://www.aphanet.org/govt/policycomm2000/pharmacobackground.html .
	Spear, Brian B., PhD, "Pharmacogenomics: Today, Tomorrow, and Beyond," Drug Benefit Trends 11(2):53-54, 1999; http://MolecularMedicine.medscape.com/SC...99/v11.n02/d5757.spea/d5757.spea-01.html .
	Stix, Gary, "Personal Pills, Genetic Differences may Dictate how Drugs are Prescribed," Scientific American: In Focus, Oct. 1998; http://www.sciam.com/1998/1098issue/1098infocus.html .
	Tanne, J. H., "The New Word in Designer Drugs," BMJ 316: pp. 1930 (1998, 27 June) http://www.bmj.com/cgi/content/full/316/7149/1930 .
	Woody, T., "DNA Detectives," TheStandard, May 22, 2000; http://www.thestandard.com/article/article_print/0,1153,15196,00 .
	Wrotnowski, Cort, "Evaluating the Market for DNA Diagnostics," Genetic Engineering News; Volume 20, Number 21, pp. 12, 14, 86-87; December 2000.
B28	Yan H et al., "Conversion of diploidy to haploidy," Nature 403(6771):723-4, Feb. 17, 1000.

EXAMINER


B. L. Lison

DATE CONSIDERED

11-21-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.



TECH CENTER 1500/2900

JUL 27 2001

RECEIVED

USPTO Form 1449 U.S. Department of Commerce
Patent and Trademark Office
**INFORMATION DISCLOSURE
CITATION**Attorney Docket No.
01107.00103Serial No.
095284,381Applicant(s): **Vogelstein, et. al.**Filing Date: **February 16, 2001**Group: **1645**

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
B21	6,022,683	February 8, 2000	Poirier	435	4	

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Country	Class	Subclass	Translation	
						YES	NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

B21	Anonymous; "Computer-Based Drug Design," http://www.axyspharm.com/technology/compdesign.html .
	Anonymous, "Genetics Media Briefing," JAMA and the Archives Journal, Science News Update, June 10, 1999, http://www.ama-assn.org/sci-pubs/sci-news/1999/snr0610.htm .
	Anonymous, "Medicines By Design: The Biological Revolution in Pharmacology," National Institute of General Medical Sciences of the National Institutes of Health; April 30, 1997; http://www.nigms.nih.gov/news/science_ed/medbydes.html .
	Anonymous, "Pharmacogenomics," http://www.axyspharm.com/technology/pharmacogenomics.html .
	Anonymous, "Pharmacogenomics," U.S. Department of Energy Office of Science, Office of Biological and Environmental Research, Human Genome Program, January 11, 2001; http://www.ornl.gov/hgmis/medicine/pharma.html .
	Anonymous; "Pharmacogenomics: A new approach to targeting therapies," http://www.pjbpubs.com/sciprep/bs953.htm .
	Basu, J., "Genetic Roulette: The Human Genome Project is Ushering in a Biotech Revolution. Who's Watching Out for Your future in this Brave New World?" Stanford Today, Nov./Dec., 1996; http://www.stanford.edu/dept/news/stanfordtoday/ed/9611/9611fea .
	Bullock, P. L., PhD; "Pharmacogenetics and Its Impact on Drug Development," Drug Benefit Trends 11(1):53-54, 1999; http://www.medscape.com/SCP/DBT/1999/v11/n01/d5732.bull/d5732.bull-01.html .
	Cantor, C. R., PhD, "Pharmacogenomics and the Future of Medicine," GeneLetter 1(3), April, 2000; http://www.wysiwig.com/188/http://207.230.125.193/pro.../04-01-00/features/pharmacogenomics.html .
B21	Jenkins, J. F., PhD, RN, "An Historical Perspective On Genetic Care," Nursing World: Online Journal of Issues in Nursing, Vol. 5, No. 3, September 30, 2000; http://nursingworld.org/ojin/topic13/tpc13_2 .

EXAMINER

B. J. Lison

DATE CONSIDERED

11-21-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.